By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer ...

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged ...

July 10 (Reuters) - British drugmaker GSK said on Friday its experimental drug for treating patients with advanced or ...

New research from VCU Massey Comprehensive Cancer Center provides evidence for a combination treatment strategy that uses ...

A preclinical study finds that combining atovaquone with platelet-derived growth factor receptor inhibitors reduced ovarian cancer tumoroid viability.

A medication that has long been used to treat high blood pressure could also help make an important class of cancer drugs ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

A newly identified inflammatory signaling target may help weaken the protective environment surrounding pancreatic tumors and ...

Scientists have expressed ‘excitement’ over the potential new treatment for advanced adrenocortical carcinoma (ACC) ...

While the search for novel therapeutics remains essential, researchers are placing greater emphasis on understanding how the ...